RenovoRx Announced A Strategic Research Collaboration To Optimize The Delivery Of Imugene's Oncolytic Virus Therapy With RenovoRx's Trans-Arterial Micro-Perfusion Therapy Platform For Difficult-To-Access Tumors
Portfolio Pulse from Benzinga Newsdesk
RenovoRx has announced a strategic research collaboration with Imugene to optimize the delivery of Imugene's oncolytic virus therapy using RenovoRx's Trans-Arterial Micro-Perfusion therapy platform for difficult-to-access tumors.
July 20, 2023 | 11:58 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RenovoRx's collaboration with Imugene could potentially enhance the effectiveness of their Trans-Arterial Micro-Perfusion therapy platform, potentially leading to increased demand and positive impact on the stock.
The collaboration with Imugene could potentially enhance the effectiveness of RenovoRx's Trans-Arterial Micro-Perfusion therapy platform. If successful, this could lead to increased demand for the platform, which could have a positive impact on RenovoRx's stock price in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100